Metsera, Inc. (NASDAQ:MTSR - Free Report) - Analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for Metsera in a research note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst P. Agrawal forecasts that the company will earn ($3.81) per share for the year. Cantor Fitzgerald has a "Overweight" rating on the stock.
Metsera (NASDAQ:MTSR - Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The company reported ($1.03) EPS for the quarter.
MTSR has been the subject of a number of other reports. Bank of America initiated coverage on shares of Metsera in a research report on Tuesday, February 25th. They set a "buy" rating and a $38.00 target price for the company. Guggenheim upped their price objective on Metsera from $56.00 to $62.00 and gave the company a "buy" rating in a research note on Tuesday. Finally, Evercore ISI assumed coverage on Metsera in a report on Tuesday, February 25th. They set an "outperform" rating for the company.
View Our Latest Report on MTSR
Metsera Price Performance
Shares of NASDAQ MTSR traded up $1.52 during mid-day trading on Wednesday, reaching $34.58. 482,327 shares of the company's stock traded hands, compared to its average volume of 910,908. The business has a 50-day moving average of $24.08. Metsera has a 1-year low of $12.30 and a 1-year high of $37.99.
Institutional Investors Weigh In On Metsera
A number of hedge funds and other institutional investors have recently bought and sold shares of MTSR. Strs Ohio bought a new position in shares of Metsera during the first quarter valued at $76,000. New York State Common Retirement Fund bought a new position in Metsera in the 1st quarter worth about $131,000. Corebridge Financial Inc. purchased a new stake in Metsera during the 1st quarter valued at about $206,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in Metsera during the 1st quarter valued at about $248,000. Finally, MetLife Investment Management LLC purchased a new position in Metsera in the first quarter worth about $254,000.
About Metsera
(
Get Free Report)
Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
See Also
Before you consider Metsera, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Metsera wasn't on the list.
While Metsera currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
